Sign in

CIK 0001347178

  • Accelerated filer

Vanda Pharmaceuticals Inc.

Sign in to watch
Ticker
VNDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
030491827
Phone
+1 202-734-3400
Business address
2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
  1. 4 Open-market sale President and CEO sold 125,252 shares at an average $13.04 ($1,633,510)
  2. 4 Open-market sale SVP, Chief Marketing Officer sold 3,710 shares at $11.08 ($41,109)
  3. 4 Open-market sale SVP & General Counsel sold 3,684 shares at $11.81 ($43,526)
  4. 4 Open-market sale Chief Corp. Affairs Officer sold 7,200 shares at $11.81 ($85,018)
  5. 4 Grant or award SVP, CFO & Treasurer acquired 17,344 shares (grant or award)
  6. 4 Open-market sale Chief Corp. Affairs Officer sold 7,313 shares at $10.62 ($77,631)
  7. 4 Grant or award Director acquired 5,000 shares (grant or award)
  8. 4 Grant or award Director acquired 5,000 shares (grant or award)
  9. 4 Grant or award Director acquired 5,000 shares (grant or award)
  10. 4 Grant or award Director acquired 5,000 shares (grant or award)
  11. 4 Grant or award Director acquired 5,000 shares (grant or award)
  12. 4 Open-market sale Director sold 9,677 shares at $11.50 ($111,286)
  13. 4 Open-market sale Director sold 10,129 shares at $11.04 ($111,806)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Open-market sale SVP & General Counsel sold 4,385 shares at an average $10.36 ($45,440)
  16. 4 Open-market sale SVP & Chief Commercial Officer sold 1,450 shares at $10.18 ($14,755)
  17. 4 Open-market sale President and CEO sold 15,580 shares at an average $10.70 ($166,756)
  18. 4 Open-market sale EVP & Chief Financial Officer sold 18,857 shares at an average $10.36 ($195,446)
  19. 4 Open-market sale SVP, Business Development sold 17,758 shares at an average $10.23 ($181,670)
  20. 4 Grant or award SVP & General Counsel acquired 30,000 shares (grant or award)

Page 8 of 29 · 579 filings